
Photo: Depositphotos
Aug 16, 2025, 11:26
New Clinical Trial Explores WRN Helicase Inhibitor MOMA-341 in GI Cancers Resistant to Immunotherapy
Tiago Biachi de Castria, Medical Oncologist, Associate Member at Moffitt Cancer Center, Associate Professor at University of South Florida, shared a post on LinkedIn:
“Phase 1 trial with MOMA-341 is now open at Moffitt (NCT06974110)! This is a potent WRN helicase inhibitor with great preclinical activity in MSI-H tumors and a great option for our GI cancers patients with primary or acquired resistance to IO.”
More posts featuring Tiago Biachi de Castria on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 16, 2025, 11:12
Aug 16, 2025, 11:07
Aug 16, 2025, 11:03
Aug 16, 2025, 09:52